右美托咪定减少难治性脓毒性休克血管升压药抵抗:α2激动剂右美托咪定用于难治性脓毒性休克(ADRESS):双盲随机对照先导试验
ADRESS为法国5个ICU开展的多中心、随机、安慰剂对照、双盲先导试验,纳入脓毒性休克(Sepsis-3定义)且去甲肾上腺素≥0.25 µg/kg/min(酒石酸去甲肾上腺素0.5 µg/kg/min)、持续循环衰竭(乳酸>2 mmol/L、少尿或皮肤花斑)并有创机械通气的患者。计划纳入36例,因右美托咪定组死亡率更高而提前终止,实际纳入32例。右美托咪定固定剂量1 µg/kg/hr,主要终点为6小时去氧肾上腺素升压反应,右美托咪定组低于安慰剂组(1.26±0.23 vs 1.45±0.26;p=0.048),但基线也存在差异(p=0.029)。两组累积去甲肾上腺素剂量、乳酸、SOFA评分、液体平衡、无通气天数及心动过缓发生率无显著差异;第3天死亡率右美托咪定组更高,差异在30天和90天缩小且不再显著。结论认为基线即存在的升压反应差异可能促成早期死亡率升高,妨碍对右美托咪定在难治性脓毒性休克中疗效的结论。
要点
- 纳入标准:脓毒性休克(Sepsis-3)且去甲肾上腺素≥0.25 µg/kg/min(酒石酸去甲肾上腺素0.5 µg/kg/min)、持续循环衰竭(乳酸>2 mmol/L、少尿或皮肤花斑)并有创机械通气。
- 右美托咪定固定剂量1 µg/kg/hr,6小时去氧肾上腺素升压反应低于安慰剂组(1.26±0.23 vs 1.45±0.26;p=0.048),但基线即存在差异(p=0.029)。
- 因右美托咪定组死亡率更高,研究提前终止,实际纳入32例(计划36例)。
- 第3天死亡率右美托咪定组高于安慰剂组,差异在30天和90天缩小且不再显著。
- 两组累积去甲肾上腺素剂量、乳酸、SOFA评分、液体平衡、无通气天数及心动过缓发生率无显著差异。
适用人群与场景
- 脓毒性休克(Sepsis-3定义)且去甲肾上腺素需要量≥0.25 µg/kg/min(酒石酸去甲肾上腺素0.5 µg/kg/min),伴持续循环衰竭(乳酸>2 mmol/L、少尿或皮肤花斑)并有创机械通气的患者。
- 研究在法国5个ICU进行。
诊断标准与关键阈值
- 脓毒性休克采用Sepsis-3定义。
- 难治性状态定义:去甲肾上腺素≥0.25 µg/kg/min(酒石酸去甲肾上腺素0.5 µg/kg/min)且持续循环衰竭(乳酸>2 mmol/L、少尿或皮肤花斑)。
- 需有创机械通气。
处置流程与药物剂量
- 右美托咪定组给予固定剂量1 µg/kg/hr;安慰剂组给予安慰剂。
- 在开始治疗前(0小时)、6小时(主要终点)和12小时测量去氧肾上腺素升压反应。
研究设计与关键结果
- 多中心、随机、安慰剂对照、双盲先导试验,法国5个ICU,计划纳入36例,因右美托咪定组死亡率更高而提前终止,实际纳入32例。
- 6小时去氧肾上腺素升压反应:右美托咪定组1.26±0.23 vs 安慰剂组1.45±0.26,p=0.048;基线时两组也存在差异,p=0.029。
- 两组累积去甲肾上腺素剂量、乳酸、SOFA评分、液体平衡、无通气天数及心动过缓发生率无显著差异。
- 第3天死亡率右美托咪定组高于安慰剂组,差异在30天和90天缩小且不再显著。
- 右美托咪定组心率未降低。
证据类型、等级与局限
- 证据类型:多中心、随机、安慰剂对照、双盲先导试验。
- 因右美托咪定组死亡率更高而提前终止,实际纳入32例(计划36例)。
- 基线去氧肾上腺素升压反应存在差异(p=0.029),可能影响主要终点解释。
- 作者结论:基线即存在的升压反应差异可能促成右美托咪定组早期死亡率升高,妨碍对右美托咪定在难治性脓毒性休克中疗效的结论。
对床旁实践的改变
- 作者认为,右美托咪定组在所有研究时间点(包括基线)去氧肾上腺素升压反应显著更低,可能促成早期死亡率升高,妨碍对右美托咪定在难治性脓毒性休克中疗效的结论。
- 研究因右美托咪定组死亡率更高而提前终止,第3天死亡率右美托咪定组高于安慰剂组。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: Increasing evidence has suggested the benefits of dexmedetomidine in patients with sepsis. Dexmedetomidine may increase vasopressor sensitivity, which may be of interest in the setting of refractory septic shock. The α2 Agonist Dexmedetomidine for REfractory Septic Shock (ADRESS) pilot study aimed to evaluate the effect of dexmedetomidine on the vasopressor response in patients with refractory septic shock.
DESIGN: This study was a multicenter, randomized, placebo-controlled, double-blind pilot trial.
SETTING: The study was conducted in 5 ICUs in France.
PATIENTS: Inclusion criteria were septic shock (Sepsis-3 definition) and norepinephrine requirement greater than or equal to 0.25 µg/kg/min (0.5 µg/kg/min of norepinephrine tartrate) with persistent circulatory failure (defined by lactate > 2 mmol/L, oliguria, or skin mottling) and invasive mechanical ventilation.
INTERVENTIONS: The arterial pressure response to phenylephrine was measured before starting the treatment (0 hr), at 6 hours (primary outcome), and 12 hours. In the treatment arm, dexmedetomidine was given at a fixed dose of 1 µg/kg/hr.
MEASUREMENTS AND MAIN RESULTS: Inclusions were stopped early because of higher mortality in the dexmedetomidine arm. Thirty-two patients of the 36 planned were included. Response to phenylephrine at 6 hours was lower in the dexmedetomidine group than in the placebo group (1.26 ± 0.23 vs. 1.45 ± 0.26; p = 0.048), although this difference was also observed at baseline ( p = 0.029). There were no significant differences between the groups in terms of cumulative norepinephrine dose, lactatemia, Sequential Organ Failure Assessment score, fluid balance, ventilation-free days, or occurrence of bradycardia. Mortality on day 3 was higher in the dexmedetomidine group than in the placebo group, with a difference that diminished and was no longer significant on 30 and 90 days.
CONCLUSIONS: Patients in the dexmedetomidine arm had a significantly lower response to phenylephrine at all study times including baseline, which might have contributed to higher early mortality in the dexmedetomidine arm and preclude to conclude on dexmedetomidine efficacy in refractory septic shock. However, heart rate was not decreased in the dexmedetomidine arm.
参考来源
- Dargent A, Bourredjem A, Jacquier M, et al. Dexmedetomidine to Reduce Vasopressor Resistance in Refractory Septic Shock: α2 Agonist Dexmedetomidine for REfractory Septic Shock (ADRESS): A Double-Blind Randomized Controlled Pilot Trial. Crit Care Med. 2025. PMID: 40019329. doi:10.1097/CCM.0000000000006608
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。